8.1.6. Tremelimumab and PF-06801591 Immunogenicity For patients receiving tremelimumab, the percentage of subjects with positive ADA and neutralizing antibodies will be summarized by dosing cohort. For patients with positive ADA, the magnitude (titer), time of onset, and duration of ADA response will also be described, if data permit. For patients receiving PF-06801591, the percentage of subjects with positive ADA and neutralizing antibodies will be summarized by dosing cohort. For patients with positive ADA, the magnitude (titer), time of onset, and duration of ADA response will also be described, if data permit. CCI Protocol B7791001 Statistical Analysis Plan PFIZER CONFIDENTIAL Page 24 CCI Protocol B7791001 Statistical Analysis Plan PFIZER CONFIDENTIAL Page 259.REFERENCES 1. Nishino M, Jagannathan JP, Krajewski KM, O'Regan K, Hatabu H, Shapiro G, Ramaiy a NH. Personalized tumor response assessment in the era of molecular medicine: cancer - specific and therap y-specific response criteria to complement pitfalls of RECI ST. AJR Am J Roentgenol 2012;198(4):737 –745.